AGTC -4%, presumably in sympathy move with AAVL. This is silly, however, insofar as all of AGTC’s gene-therapy programs are in rare (monogenic) ophthalmic diseases.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”